Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Mol Pharm. 2015 May 4;12(6):2101–2111. doi: 10.1021/acs.molpharmaceut.5b00071

Figure 8. CD19-DOX-NPs enhance therapeutic efficacy and prolongs survival in pre-clinical leukemia mouse models (8 per treatment group).

Figure 8

Efficacy of CD19-DOX-NPs in xenograft model of ALL. (Survival rate is presented in a Kaplan-Meier plot). CD19-DOX-NPs (≈2.5 mg/kg DOX) significantly prolonged survival in comparison with groups treated with saline, IgG-DOX-NPs and free DOX (≈2.5 mg/kg DOX).